Literature DB >> 21717265

Clinical outcomes of atypical extra-esophageal reflux symptoms following laparoscopic antireflux surgery.

Shaun R Brown1, C Prakash Gyawali, Lora Melman, Eric D Jenkins, Julia Bader, Margaret M Frisella, L Michael Brunt, J Christopher Eagon, Brent D Matthews.   

Abstract

INTRODUCTION: While it is well established that antireflux surgery is effective in relieving typical gastroesophageal reflux disease (GERD) symptoms such as heartburn and regurgitation, it is currently unclear whether atypical symptoms (cough, hoarseness, wheeze) foreshadow a less satisfactory outcome following laparoscopic antireflux surgery (LARS). The purpose of this study is to critically analyze the clinical outcomes of atypical symptoms in patients undergoing LARS.
METHODS: Patients scheduled for LARS for GERD were prospectively enrolled over a 7-year period; all subjects underwent preoperative high-resolution manometry (HRM) and had evidence of GERD on ambulatory pH study. Cough, wheeze, and hoarseness were considered atypical symptoms. During preoperative and postoperative examinations, patients completed detailed foregut symptomatology questionnaires, using both 5-point Likert and 10-point visual analog scales (VAS) to document typical as well as atypical symptoms. Atypical symptom burden was calculated as a sum of VAS for the three atypical symptoms, termed the atypical score (ATS). HRM patterns were grouped into normal, spastic, and hypomotile. Statistical significance (p < 0.05) was determined using paired t-test, and analysis of variance with post hoc least significant difference (LSD).
RESULTS: One hundred thirteen patients (age 49 ± 1.26 years, range 20-84 years, M:F 47:66) with mean follow-up of 28 ± 2.31 months (range 1-92 months) fulfilled inclusion criteria, having mean modified DeMeester score of 45.5 ± 2.78. Heartburn was noted in 84.1%, while atypical symptoms of some degree were reported by 92.0% (104 patients). Heartburn improved from a preoperative score of 7.1 ± 0.54 to 0.9 ± 0.24 after LARS, and ATS improved from 8.9 ± 0.71 to 2.2 ± 0.42. Significant improvements were noted for all atypical symptoms analyzed (p < 0.0001 for each). Improvement in atypical symptoms was least in the presence of hypomotility features on HRM (21.7% improvement), compared with normal motility (72.4%) and spastic features (83.9%). Preoperative atypical score (p < 0.0001) and esophageal hypomotility (p = 0.04) demonstrated a linear relationship with postoperative atypical score.
CONCLUSIONS: In an unselected cohort of patients undergoing LARS, atypical GERD symptoms improved as significantly as typical symptoms. Symptom improvement was significantly lower in the presence of esophageal hypomotility and with higher symptomatic state. Therefore, patients with severe atypical symptoms or hypomotile esophagus may not achieve the same clinical satisfaction from LARS.

Entities:  

Mesh:

Year:  2011        PMID: 21717265     DOI: 10.1007/s00464-011-1806-y

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  24 in total

Review 1.  Review article: extraoesophageal manifestations of gastro-oesophageal reflux disease.

Authors:  J E Richter
Journal:  Aliment Pharmacol Ther       Date:  2005-08       Impact factor: 8.171

2.  Ten-year outcome of laparoscopic antireflux surgery.

Authors:  M Fein; M Bueter; A Thalheimer; V Pachmayr; J Heimbucher; S M Freys; K-H Fuchs
Journal:  J Gastrointest Surg       Date:  2008-09-03       Impact factor: 3.452

3.  Laparoscopic vs conventional Nissen fundoplication. A prospective randomized study.

Authors:  S Laine; A Rantala; R Gullichsen; J Ovaska
Journal:  Surg Endosc       Date:  1997-05       Impact factor: 4.584

4.  Results of laparoscopic fundoplication where atypical symptoms coexist with oesophageal reflux.

Authors:  R Y Chen; R J Thomas
Journal:  Aust N Z J Surg       Date:  2000-12

5.  Influence of spastic motor disorders of the esophageal body on outcomes from laparoscopic antireflux surgery.

Authors:  E R Winslow; R E Clouse; K M Desai; P Frisella; T Gunsberger; N J Soper; M E Klingensmith
Journal:  Surg Endosc       Date:  2003-03-07       Impact factor: 4.584

6.  Acceptability of visual analogue scales in the clinical setting: a comparison with verbal rating scales in postoperative pain.

Authors:  J E Baños; F Bosch; M Cañellas; A Bassols; F Ortega; J Bigorra
Journal:  Methods Find Exp Clin Pharmacol       Date:  1989-02

7.  Abnormal GERD parameters on ambulatory pH monitoring predict therapeutic success in noncardiac chest pain.

Authors:  Vladimir M Kushnir; Gregory S Sayuk; C Prakash Gyawali
Journal:  Am J Gastroenterol       Date:  2009-11-17       Impact factor: 10.864

8.  Long-term therapeutic outcome of patients undergoing ambulatory pH monitoring for chronic unexplained cough.

Authors:  Michael J Hersh; Gregory S Sayuk; C Prakash Gyawali
Journal:  J Clin Gastroenterol       Date:  2010-04       Impact factor: 3.062

9.  Effects of manometrically discovered nonspecific motility disorders of the esophagus on the outcomes of antireflux surgery.

Authors:  Vic Velanovich; Arvind Mahatme
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

Review 10.  Cough and gastroesophageal reflux: from the gastroenterologist end.

Authors:  Ans Pauwels; Kathleen Blondeau; Lieven Dupont; Daniel Sifrim
Journal:  Pulm Pharmacol Ther       Date:  2008-11-27       Impact factor: 3.410

View more
  10 in total

1.  24-h multichannel intraluminal impedance-pH monitoring may be an inadequate test for detecting gastroesophageal reflux in patients with mixed typical and atypical symptoms.

Authors:  Michelle S Han; Michal J Lada; Dylan R Nieman; Andreas Tschoner; Christian G Peyre; Carolyn E Jones; Thomas J Watson; Jeffrey H Peters
Journal:  Surg Endosc       Date:  2014-11-15       Impact factor: 4.584

Review 2.  What Is the Impact of High-Resolution Manometry in the Functional Diagnostic Workup of Gastroesophageal Reflux Disease?

Authors:  Jutta Keller
Journal:  Visc Med       Date:  2018-04-12

3.  Outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease in non-responders to proton pump inhibitors.

Authors:  Emad Hamdy; Ayman El Nakeeb; Hosam Hamed; Mohamed El Hemaly; Nabil Gad ElHak
Journal:  J Gastrointest Surg       Date:  2014-07-02       Impact factor: 3.452

Review 4.  Surgical Treatment of Extraesophageal Manifestations of Gastroesophageal Reflux Disease.

Authors:  Feroze Sidwa; Alessandra L Moore; Elaine Alligood; P Marco Fisichella
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

Review 5.  Update on fundoplication for the treatment of GERD.

Authors:  Stefan Niebisch; Jeffrey H Peters
Journal:  Curr Gastroenterol Rep       Date:  2012-06

6.  [Importance of functional endoscopy for diagnostics of extraesophageal reflux : relationship of Belafsky's reflux symptom index and functional endoscopic data].

Authors:  F Michel; R Dannesberger; R Fritsche; T Stroh; P Ahrens
Journal:  HNO       Date:  2014-11       Impact factor: 1.284

7.  Treatment implications of high-resolution manometry findings: options for patients with esophageal dysmotility.

Authors:  Ahmed Bolkhir; C Prakash Gyawali
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

8.  Factors predicting outcomes of laparoscopic Nissen fundoplication for gastroesophageal reflux disease: experience at a single institution in Korea.

Authors:  Joong-Min Park; Beom Jin Kim; Jae Gyu Kim; Kyong-Choun Chi
Journal:  Ann Surg Treat Res       Date:  2017-03-24       Impact factor: 1.859

9.  British Society of Gastroenterology guidelines for oesophageal manometry and oesophageal reflux monitoring.

Authors:  Nigel J Trudgill; Daniel Sifrim; Rami Sweis; Mark Fullard; Kumar Basu; Mimi McCord; Michael Booth; John Hayman; Guy Boeckxstaens; Brian T Johnston; Nicola Ager; John De Caestecker
Journal:  Gut       Date:  2019-07-31       Impact factor: 23.059

10.  Atypical symptoms are related to typical symptoms rather than histologic and endoscopic esophagitis.

Authors:  Jung Hwan Oh
Journal:  J Neurogastroenterol Motil       Date:  2012-07-10       Impact factor: 4.924

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.